Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + rapamycin
- Development stage
- Phase 2
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Erlotinib + rapamycin is a combination therapy consisting of two small molecule inhibitors used primarily in oncology research. Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, while rapamycin (also known as sirolimus) is an inhibitor of the mammalian target of rapamycin (mTOR). The combination has been investigated for its potential to enhance antitumor activity and overcome resistance mechanisms in various cancers, including pediatric low-grade gliomas and non-small cell lung cancer. Preclinical and early clinical studies suggest that this regimen can be well tolerated, with some evidence of disease stabilization or response in select patient populations[1][2][3][4][5].
- Brand names
- Tarceva (for erlotinib)Rapamune (for sirolimus)
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on erlotinib + rapamycin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + rapamycin.